These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28923174)

  • 1. 27-Hydroxycholesterol, an endogenous selective estrogen receptor modulator.
    He S; Nelson ER
    Maturitas; 2017 Oct; 104():29-35. PubMed ID: 28923174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Endogenous Selective Estrogen Receptor Modulators such as 27-Hydroxycholesterol.
    Nelson ER
    Methods Mol Biol; 2016; 1366():431-443. PubMed ID: 26585155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.
    DuSell CD; Umetani M; Shaul PW; Mangelsdorf DJ; McDonnell DP
    Mol Endocrinol; 2008 Jan; 22(1):65-77. PubMed ID: 17872378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling.
    DuSell CD; McDonnell DP
    Trends Pharmacol Sci; 2008 Oct; 29(10):510-4. PubMed ID: 18722677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re-adopting classical nuclear receptors by cholesterol metabolites.
    Umetani M
    J Steroid Biochem Mol Biol; 2016 Mar; 157():20-6. PubMed ID: 26563834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs).
    Wardell SE; Nelson ER; McDonnell DP
    Steroids; 2014 Nov; 90():30-8. PubMed ID: 25084324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis.
    DuSell CD; Nelson ER; Wang X; Abdo J; Mödder UI; Umetani M; Gesty-Palmer D; Javitt NB; Khosla S; McDonnell DP
    Endocrinology; 2010 Aug; 151(8):3675-85. PubMed ID: 20501668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen.
    Umetani M; Domoto H; Gormley AK; Yuhanna IS; Cummins CL; Javitt NB; Korach KS; Shaul PW; Mangelsdorf DJ
    Nat Med; 2007 Oct; 13(10):1185-92. PubMed ID: 17873880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.
    Wu Q; Ishikawa T; Sirianni R; Tang H; McDonald JG; Yuhanna IS; Thompson B; Girard L; Mineo C; Brekken RA; Umetani M; Euhus DM; Xie Y; Shaul PW
    Cell Rep; 2013 Nov; 5(3):637-45. PubMed ID: 24210818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial.
    Going CC; Alexandrova L; Lau K; Yeh CY; Feldman D; Pitteri SJ
    Breast Cancer Res Treat; 2018 Feb; 167(3):797-802. PubMed ID: 29116467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity and Cancer: 27-Hydroxycholesterol, the Missing Link.
    Asghari A; Umetani M
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32650428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
    Lewis JS; Jordan VC
    Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.
    Nelson ER
    Mol Cell Endocrinol; 2018 May; 466():73-80. PubMed ID: 28919300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cholesterol metabolite 27-hydroxycholesterol promotes atherosclerosis via proinflammatory processes mediated by estrogen receptor alpha.
    Umetani M; Ghosh P; Ishikawa T; Umetani J; Ahmed M; Mineo C; Shaul PW
    Cell Metab; 2014 Jul; 20(1):172-82. PubMed ID: 24954418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction between metabolism, cancer and cardiovascular disease, connected by 27-hydroxycholesterol.
    Lee WR; Ishikawa T; Umetani M
    Clin Lipidol; 2014; 9(6):617-624. PubMed ID: 25632306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 27-Hydroxycholesterol: the first identified endogenous SERM.
    Umetani M; Shaul PW
    Trends Endocrinol Metab; 2011 Apr; 22(4):130-5. PubMed ID: 21353593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating 27-Hydroxycholesterol and Breast Cancer Risk: Results From the EPIC-Heidelberg Cohort.
    Lu DL; Le Cornet C; Sookthai D; Johnson TS; Kaaks R; Fortner RT
    J Natl Cancer Inst; 2019 Apr; 111(4):365-371. PubMed ID: 30016454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol and breast cancer pathophysiology.
    Nelson ER; Chang CY; McDonnell DP
    Trends Endocrinol Metab; 2014 Dec; 25(12):649-55. PubMed ID: 25458418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence of pomegranate methanolic extract in antagonizing the endogenous SERM, 27-hydroxycholesterol.
    Vini R; Juberiya AM; Sreeja S
    IUBMB Life; 2016 Feb; 68(2):116-21. PubMed ID: 26756990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ROS-mediated activation of STAT-3/VEGF signaling is involved in the 27-hydroxycholesterol-induced angiogenesis in human breast cancer cells.
    Zhu D; Shen Z; Liu J; Chen J; Liu Y; Hu C; Li Z; Li Y
    Toxicol Lett; 2016 Dec; 264():79-86. PubMed ID: 27856279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.